Leading Organisation to Anchor Canary Wharf Cluster

Genomics England, a global leader in advancing and delivering genomic medicine and genomic research, is moving its headquarters to London’s Canary Wharf during autumn, following the announcement in March of a joint venture by Canary Wharf Group (CWG) and Kadans Science Partner to develop a life science focused laboratory on the London site, as the first phase of plans for a leading health and life sciences cluster.

With 750,000 sq ft of space across 22 storeys, situated on the 3.3-hectare North Quay site located next to the new Elizabeth line station, the new facility, to be delivered in 2026, will be the largest commercial, wet lab enabled life science building in Europe. It will offer flexibility for core laboratory space on all floors and house SME’s and academics as well as global healthcare and pharmaceutical companies creating a campus under one roof.

The London site is already home to several leading healthcare and life sciences-focused organisations, including Barts Health NHS Trust, the Medicines and Healthcare Products Regulatory Agency, Medical Defence Union, General Pharmaceutical Council and NHS Transformation.

”Securing a company of Genomics England’s stature is a significant endorsement of our vision to establish Canary Wharf as a world class life sciences hub in the UK. Canary Wharf offers Genomics England an unrivalled and exceptional working environment with access to great transport, power and cloud infrastructure, more than 300 shops and restaurants, 20 acres of green spaces and 5 km of waterside boardwalks,” said  Shobi Khan, CEO of Canary Wharf Group

“Attracting a cluster of innovative companies to Canary Wharf, in advance of opening our purpose-built laboratory enabled space at North Quay, is part of our strategy to make Canary Wharf one of the UK’s leading centres for life sciences.”

Chris Wigley, CEO of Genomics England Limited added: “Genomics England is delivering an ambitious agenda, in partnership with the NHS and others that will ensure the UK continues to lead the world in genomics. The move to Canary Wharf will enable us to deliver this agenda more effectively, benefitting our workforce as well as moving us to a more modern estate in close proximity to our partners in the NHS and Life Sciences sector.”

Having enabled the world's first national Whole Genome Sequencing service in the NHS Genomic Medicine Service, Genomics London helps researchers use the data to help find the causes of diseases and to work on new treatments. At the cutting edge of global research into the human genome, it is regarded as one of the most valuable organisations of the UK’s life science sector.

Canary Wharf Group was advised by CBRE and JLL, SHB Real Estate acted for Genomics England.

More information online